Infla

Quick links to important sections

Infla

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Infla

What is Infla? A Multimodal Combination

Property Description
Active Ingredients Diacerein, Glucosamine, Methyl Sulfonyl Methane (MSM), Paracetamol
Form Oral Solid Form (e.g., tablet or capsule)
Pharmacological Class Symptomatic Slow-Acting Drug in Osteoarthritis (SYSADOA), Analgesic
Common Use Management of degenerative joint conditions
Origin Mixed (Synthetic and Supplement-Derived)

What is Infla and What Type of Drug is it?

Infla is a multimodal, fixed-dose combination medicine formulated as an oral solid form for managing degenerative joint conditions. It is primarily classified as a Symptomatic Slow-Acting Drug in Osteoarthritis (SYSADOA), possessing a distinct analgesic component, which establishes its dual role in addressing both pain and structural joint health.

The classification as a fixed-dose combination signifies that it unifies several distinct therapeutic components into one unit, specifically intended for adult patients seeking long-term joint care solutions. The SYSADOA category refers to its intended slow-onset, long-term effect of addressing the underlying joint pathology. Research affirms the role of SYSADOA components, such as Glucosamine and Diacerein, in managing symptoms associated with osteoarthritis. The general conclusion is that this type of medication is designed to provide therapeutic effects that develop gradually over time, promoting joint comfort and function.

Composition: The Four Active Ingredients and Form

Infla's efficacy is based on the combined action of its four active ingredients: Diacerein, Glucosamine, Methyl Sulfonyl Methane (MSM), and Paracetamol (Acetaminophen). These components are delivered via the oral route.

The components reflect a mixed origin: Diacerein and Paracetamol are synthetically derived, while Glucosamine and MSM are utilized as pharmaceutical-grade supplements. Diacerein is recognized as an anthraquinone derivative that acts as an Interleukin-1 beta (IL-1beta) inhibitor, a property that has been clinically recognized for its anti-catabolic function. This means the drug contains agents that help protect the joint tissue from breakdown, a differentiating feature compared to pain-only medications.

General Purpose: How Infla Supports Joint Health

The general purpose of Infla is to provide symptomatic relief from joint pain while concurrently supporting the integrity and function of the joint cartilage.

The design of the product is intended to provide a synergistic action, managing discomfort and slowing the progression of cartilage degradation. By integrating an analgesic with agents that inhibit destructive enzymes and stimulate matrix repair, Infla aims to optimize the joint's internal environment. This multi-target approach makes Infla a frequent choice in the conservative management of mild to moderate knee osteoarthritis. The final therapeutic goal is to help improve the patient's long-term mobility and overall quality of life related to joint function.

Regulatory References

  1. Summary of EMA Review on Diacerein (2014)

What side effects are possible with Infla?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety considerations for Infla, based on governmental regulatory documents for its therapeutic class.

Key Adverse Reaction Scope

Regulatory warnings emphasize the potential for serious cardiovascular thrombotic events, including myocardial infarction and stroke, which may be fatal. These risks may increase with the duration of use and higher doses. Another major safety concern is the potential for serious gastrointestinal adverse events, such as bleeding, ulceration, and perforation of the stomach or intestines, which can also be fatal.

Key system-organ classes involved include the Cardiovascular system, Gastrointestinal system, Renal system, and Hepatic system. Other documented adverse reactions encompass hypersensitivity reactions (e.g., anaphylactoid reactions), severe skin reactions, and hepatic/renal dysfunction.

Safety Classifications and Limitations

Serious risks associated with this drug class often necessitate the use of a Boxed Warning (the strongest warning required by the FDA) in regulatory labeling to highlight the life-threatening nature of these events.

Population-Specific Safety Considerations:

  • Pregnancy: Contraindicated from 20 weeks onward due to risk of fetal kidney issues and potential for premature closure of the fetal ductus arteriosus in the third trimester.
  • Surgery: Contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery.
  • High-Risk Patients: Requires caution in patients with pre-existing cardiovascular disease, hypertension, renal impairment, or older age.

Safety Restrictions: Infla is contraindicated in patients with known hypersensitivity, active gastrointestinal bleeding or ulceration, and severe uncontrolled heart failure. Treatment should be discontinued immediately at the first sign of any serious adverse reaction.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation defines the overdose profile for Infla as a high-risk situation requiring immediate emergency action. The most severe concern is the potential for Acute Liver Failure and Hepatic Necrosis, which are explicitly documented life-threatening outcomes of the Acetaminophen component. Initial signs of overdose may include non-specific gastrointestinal distress, such as nausea, vomiting, abdominal pain, pallor, and diaphoresis (sweating). Due to the Diacerein component, severe diarrhea and subsequent fluid and electrolyte loss are also noted manifestations.


Emergency Action and Treatment

Immediate medical attention is required for any suspected overdose, even if the person appears asymptomatic, to prevent the delayed onset of fatal hepatotoxicity. The regulatory mandate specifies that emergency services or a Poison Control Center must be contacted at once. Management requires hospital monitoring and supportive measures, including the administration of N-acetylcysteine (NAC), which is the specific antidote for Acetaminophen toxicity. Timely administration of NAC is critical to the official treatment protocol. Monitoring involves serial testing of plasma concentrations and Liver Function Tests (LFTs) to assess injury. Overdose risk is documented as being increased in patients with pre-existing hepatic impairment.

Therapeutic Uses of Infla

What Infla Treats: Main Uses and Benefits

Infla is considered relevant when short-term symptomatic assistance is needed across several common clinical domains. It provides support that helps ease the overall symptom burden and assists with maintaining functional stability when symptoms are more noticeable. Symptomatic relief, particularly for issues like acute or episodic discomfort, is commonly used to help with medical management.

Infla may be part of symptomatic management for conditions characterized by episodic or fluctuating manifestations, and is often used when symptoms intensify and supportive relief is needed. The medicine is relevant in situations involving symptoms related to physical discomfort, symptoms associated with acute or episodic changes, and symptoms that interfere with daily functioning.

Used in situations involving certain distressing symptoms

Quick Fact: Focus: Supportive Care for Symptom Clusters

Support During Symptom Flare-ups

Infla is applied when groups of symptoms appear suddenly or fluctuate, creating noticeable interference with routine activities. It contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable. It supports patients during difficult episodes by easing distress in areas where short-term symptom management is appropriate.

Regulatory References

  1. NIH MedlinePlus overview on Pain

Eligibility and Restrictions for Use

The eligibility profile for Infla, a multimodal combination medicine, is strictly defined by the regulatory requirements for its active components. Use is established only for adult populations.

Category Official Regulatory Status
Contraindications Use is prohibited in patients with active liver disease or a history of liver disease, as well as those with inflammatory organic bowel disease (e.g., Crohn’s or Ulcerative Colitis). Contraindicated in known hypersensitivity to any component or anthraquinone derivatives.
Age-Related Rules Not recommended for use in children and adolescents (under 15 or 18 years). Use in older adults aged 65 years and above is also not recommended due to specific safety risks documented by regulatory authorities.
Reproductive Status Contraindicated or not recommended for women who are pregnant or breastfeeding.
Conditional Use Patients with severe renal insufficiency require specific supervision. Caution is advised for those with diabetes or known shellfish allergy.

The official labeling classifies the use in severe liver disease, inflammatory bowel disease, and pregnancy as an absolute contraindication. The restrictions for geriatric and pediatric populations are classified as not recommended or not established, strictly limiting eligibility to generally healthy, non-pregnant adults who do not possess these excluded comorbidities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Infla is a fixed-dose combination, and its official interaction profile is structured by constraints from its four components: Paracetamol, Diacerein, Glucosamine, and MSM. The most significant constraint is the formal prohibition on co-administering Infla with any other medicinal product containing Acetaminophen (Paracetamol). This is a regulatory constraint designed to prevent excessive total daily exposure, which carries a documented risk of severe liver damage and acute liver failure.

Interactions that alter drug activity or exposure require caution. The combination results in increased anticoagulant activity when co-administered with Warfarin and related agents, which is officially tracked as an increase in the International Normalized Ratio (INR). To manage absorption, Antacids (aluminum, calcium, or magnesium salts) require a mandatory separation of administration by greater than 2 hours from Infla due to documented decreases in Diacerein absorption.

Pharmacodynamic constraints exist for cardiac-acting drugs. Co-administration with Diuretics or Cardiac Glycosides increases the documented risk of arrhythmia, a consequence of the potential for dehydration and hypokalemia caused by the Diacerein component. Patients are advised to limit alcohol intake due to the combined hepatic risk from both the Paracetamol and Diacerein components. Regulatory documents also note that individuals with underlying Liver Disease have a higher risk of acute liver failure with the Paracetamol component.

Mechanism of Action

The action of Infla is achieved by influencing three distinct biological domains, resulting in a multi-target engagement of joint physiology and pain signaling.


Modulating Cartilage Catabolism and Inflammatory Signaling

This mechanism involves two key anti-destructive actions: Diacerein is metabolized to rhein, which inhibits the pro-inflammatory cytokine IL-1beta, thereby reducing the synthesis of cartilage-degrading enzymes. Concurrently, Methyl Sulfonyl Methane (MSM) acts as an antioxidant and inhibits the NF-kappa B pathway. This combined action facilitates the suppression of inflammatory signaling and supports the stability of the cartilage matrix structure.

Supporting Cartilage Anabolic Pathways

This domain is driven by Glucosamine, which serves as an essential precursor. By supplying this substrate, the mechanism actively supports the chondrocytes in the synthesis and incorporation of key structural molecules like proteoglycans and Glycosaminoglycans (GAGs). This physiological support contributes to the retention of structural integrity and elastic properties of the joint tissue.

Central Control of Nociceptive Signals

The mechanism of Paracetamol primarily occurs within the Central Nervous System (CNS), involving the inhibition of specific COX isoforms and modulation of the endocannabinoid system. This central action leads to an elevation of the nociceptive threshold and alters pain signal transmission, influencing physiological response independently of the slower-acting peripheral components.

Dosage and Administration Information

How to Use Infla: Official Administration Guidelines

Infla is prescribed for oral administration as a fixed-dose solid unit, typically a tablet or capsule. Usage follows specific guidelines, establishing the required regimen for its active ingredients, which include Diacerein, Glucosamine, MSM, and Paracetamol.


Standard Regimen and Timing

Guideline Official Instruction
Route of Administration Oral ingestion of the solid unit.
Dosing Schedule One unit taken twice daily (BID). The maximum daily dose must not exceed two units.
Timing with Meals Must be administered with food or immediately following a meal (e.g., breakfast and dinner).
Duration Pattern Used as part of a long-term continuous treatment course, typically lasting 3 to 6 months or longer.

Procedural and Population-Specific Rules

Each unit must be swallowed whole with water; it should not be crushed or chewed, as specified in regulatory documentation.

Regarding missed timing, if an administration is forgotten, the instruction is to omit the missed dose and resume the routine twice-daily schedule; taking a double dose to compensate is not permitted.

Dose adjustment is required for patients with moderate to severe renal impairment (Creatinine Clearance < 30 ml/ min), for whom the regimen is reduced to one unit per day. No specific dose alteration is typically mandated for older adults solely based on age. These requirements establish the standardized, non-advisory framework for administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Infla

Evidence Overview for Degenerative Joint Conditions

Infla is a combination drug, and the evidence base primarily consists of studies that evaluated its individual components: the symptomatic slow-acting agents (Diacerein, Glucosamine, MSM) and the fast-acting analgesic (Paracetamol). This research was used in research exploring how symptoms change over time in conditions characterized by fluctuating or episodic manifestations, such as osteoarthritis. The evidence base includes numerous Randomized Controlled Trials (RCTs) and associated Systematic Reviews, as reported in official sources, that explore short-term symptom changes and outcomes related to physical discomfort. The available evidence contributes to understanding symptom patterns in conditions where symptoms may vary in intensity.


Studies for Symptomatic and Functional Relief in Osteoarthritis

The components were studied in research involving patients diagnosed with mild to moderate osteoarthritis (OA), most commonly affecting the knee joint. These trials were applied in studies examining patient-reported experiences, which included monitoring outcomes related to physical discomfort and how these outcomes evolved over defined time intervals. Functional scales, like the WOMAC index, were used in trials assessing short-term or episodic symptom patterns, providing insight into their daily functioning and activity level.

Studies explored the effects of the SYSADOA components compared to a placebo or other active treatments. The findings describe patterns observed in the studies related to outcomes that reflect daily functioning. For the Paracetamol component, separate research examined its established use in the assessment of symptoms during episodes where discomfort becomes more noticeable. Research highlights changes measured during the study period for the combination's ingredients, providing context but not individual predictions of an outcome.


Research on Structural Outcomes and Long-Term Follow-up

The long-term study profile of the SYSADOA components was evaluated in studies extending up to 3 years. These longer studies were used in research exploring potential influences on joint integrity. The studies monitored the potential influence on joint structure by examining measurements such as minimal joint space width (JSW) over time. This metric was studied to explore the progression of the condition.

Findings help contextualize how patients reported their experience during these extended periods. However, long-term effects are not fully established regarding structural changes. Research so far indicates that data are still emerging, and certainty remains low regarding the sustained influence of the components on structural markers over extended periods.

Frequently Asked Questions (FAQ)

Common questions about Infla (FAQ)


Q: How quickly should I expect to feel the effects of Infla?

A: Infla is a combination medicine containing both slow-acting and fast-acting components. The fast-acting analgesic component (Paracetamol) is associated with providing initial symptom relief, though individual response times can vary. Because the medicine is primarily a symptomatic slow-acting drug for joint conditions, the full benefit from the entire combination may take several weeks to be noticeable.


Q: What are the most commonly reported side effects of Infla?

A: According to official product information, the most commonly reported side effects are generally mild and temporary. These may involve the digestive system and could include reports of diarrhea, nausea, abdominal pain, headache, or soft stools. Not everyone experiences these effects, and serious adverse reactions are addressed separately in the dedicated safety information section.


Q: Is Infla safe to use for people with kidney issues?

A: Official regulatory documents state that specific dose adjustment is required for individuals with moderate to severe renal impairment, which refers to reduced kidney function. The medication is typically used with caution for individuals with severe kidney impairment. This medication requires careful consideration for individuals with pre-existing kidney conditions.


Q: Can Infla interact with blood pressure medications?

A: Regulatory information indicates that co-administration with certain cardiac-acting drugs, specifically diuretics (water pills) or cardiac glycosides, increases the documented risk of arrhythmia (irregular heartbeat). This is related to the potential for dehydration and low potassium levels caused by one of the drug's components.


Q: Does Infla affect liver function?

A: Infla contains Paracetamol, which carries a documented risk of severe liver damage and acute liver failure if the total exposure is excessive. This risk is why regulatory warnings stress that the medication is typically not used for patients with active liver disease or a known history of liver disease.


Q: Does alcohol consumption change how Infla works in the body?

A: Regulatory documents include a warning regarding the need to limit alcohol intake. This is due to a combined hepatic risk (risk to the liver) from both the Paracetamol and Diacerein components, which can increase the risk of severe liver damage.


Q: Is the medication Infla used for conditions other than pain?

A: Yes, the primary use of Infla is for the management of degenerative joint conditions like osteoarthritis. Beyond pain relief, the slow-acting components are intended to influence joint physiology by supporting cartilage synthesis and inhibiting the enzymes that break down cartilage.


Q: Why is Infla sometimes prescribed with a stomach protector?

A: Official warnings emphasize the potential for serious gastrointestinal adverse events, such as bleeding, ulceration, and perforation of the stomach or intestines. To mitigate this potential safety concern, a healthcare professional may co-prescribe a gastroprotective agent.


Q: Is it normal to feel a bit dizzy when starting Infla?

A: Regulatory documents list dizziness and headache as potential side effects. These are generally mild. Individuals who experience dizziness or other nervous system effects are advised to exercise caution when performing tasks like driving or operating machinery.


Q: How long does Infla stay in your system after you stop taking it?

A: The time it takes for Infla to clear the system varies widely because it is composed of four ingredients, each with a different half-life. While the pain-relieving component clears quickly, other components have longer half-lives, meaning the overall clearance is based on the component that remains the longest.


Q: Can Infla affect sleep patterns?

A: While not a major expected effect, regulatory documentation states that adverse reaction lists for some components may include rare reports of sleep disturbances or insomnia (difficulty sleeping). This information should be considered in the context of the overall safety profile.


Q: Are there any common foods or drinks that interact with Infla?

A: Yes, official product information details one specific food-related interaction: antacids containing aluminum, calcium, or magnesium salts must be separated from Infla by greater than 2 hours. This is because these products can decrease the absorption of the Diacerein component.


Q: Can older adults (seniors) safely take Infla?

A: Use in older adults aged 65 years and above is generally not recommended by regulatory authorities. This is due to specific documented safety risks, including an increased risk of severe cardiovascular and gastrointestinal adverse events associated with this class of drug.


Q: What happens if I accidentally miss a dose of Infla?

A: Official administration instructions specify that a person should omit the missed dose and resume the routine schedule at the next scheduled time. The instructions state that taking a double dose to compensate is not permitted.


Q: What are the signs of an allergic reaction to Infla?

A: The drug carries a risk of hypersensitivity reactions, which are serious allergic responses. Signs generally include swelling of the face, tongue, or throat, hives, severe rash, or difficulty breathing. These signs are considered medical emergencies and require prompt attention.


Q: Can Infla cause changes in mood or behavior?

A: Adverse reaction lists from regulatory sources indicate that some components may rarely be associated with central nervous system effects. This means there are very rare or isolated reports of nervousness or other minor mood changes.


Q: What kind of research supports the use of Infla for chronic pain?

A: Evidence primarily consists of studies that evaluated its individual components in patients with mild to moderate osteoarthritis. These trials explored patient-reported experiences related to physical discomfort and how they scored on functional scales over defined study periods.


Q: Is Infla safe for teenagers (under 18)?

A: The use of Infla in children and adolescents, defined as those under 15 or 18 years, is officially not recommended. This is because the safety and effectiveness of the fixed-dose combination have not been established in these younger age groups according to regulatory documentation.


Q: Can Infla be taken at the same time as cold and flu medicine?

A: Regulatory constraints indicate this is not recommended. Official constraints formally prohibit co-administering Infla with any other medicinal product containing Acetaminophen (Paracetamol). This is a critical safety measure intended to prevent excessive daily exposure and the associated risk of severe liver damage.


Q: Does Infla affect blood sugar levels?

A: The Glucosamine component in Infla may affect blood sugar levels. For this reason, official warnings advise caution for individuals with diabetes. For individuals with diabetes, blood glucose monitoring may be part of the care plan when this medicine is used.


Q: Can Infla interact with birth control pills?

A: Information for the components' drug class suggests that there may be an interaction with hormonal contraceptives. For individuals taking combined hormonal contraception and a medication of this type, there may be an increased risk of venous thromboembolism (VTE).


Q: Are there different strengths of Infla available?

A: Infla is described in official documentation as a fixed-dose combination medicine. This means it is formulated into a single, standardized unit containing its four active ingredients, implying a single, standard strength is typically available.


Q: Are there specific storage requirements for Infla?

A: Yes, official documentation requires the medicine to be stored at Controlled Room Temperature, typically 68 F to 77 F (20 C to 25 C). It must also be protected from moisture and excessive heat, and must never be refrigerated.

How should Infla be stored and disposed of?

How to Store and Dispose of Infla

Infla (oral solid form) must be stored according to regulatory requirements to maintain the stability of its components.

Storage Requirements

The medicine must be kept at Controlled Room Temperature, typically 68 F to 77 F (20 C to 25 C), and should not be stored above 86 F (30 C). The product must be protected from moisture and excessive heat and must not be refrigerated. Keep Infla in its original, tightly closed container and store it out of the sight and reach of children.

Disposal Instructions

Unused or expired Infla must not be thrown away in household trash or poured into wastewater, as required by environmental guidelines. Follow local guidelines or consult a pharmacist to locate a drug take-back program for proper pharmaceutical waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Infla found in:

A-Z Index: